Thymosin Alpha-1: The Complete Drug Profile From SciClone Pharmaceuticals
Comprehensive review of thymosin alpha-1 covering hepatitis B/C trials, cancer immunotherapy, HIV studies, vaccine enhancement, and safety data — positioning it as a versatile immune-modulating peptide drug.
Quick Facts
What This Study Found
Thymosin alpha-1 demonstrates clinical efficacy across hepatitis B, hepatitis C (with IFN), cancer (with chemo), and potentially HIV, with excellent tolerability and a favorable safety profile across all studied indications.
Key Numbers
How They Did This
Comprehensive pharmaceutical review covering pharmacology, pharmacokinetics, all clinical trial data (Phase I-III), adverse effects, and dosing across multiple indications.
Why This Research Matters
This is the definitive clinical reference for thymosin alpha-1, covering everything a prescriber or researcher needs to know about this peptide drug's established and emerging clinical applications.
The Bigger Picture
Thymosin alpha-1 is one of the most clinically advanced immune peptide drugs, with a breadth of applications spanning infectious diseases, cancer, and immune reconstitution that few single agents achieve.
What This Study Doesn't Tell Us
Detailed 2002 review. Some indications had limited trial sizes. Hepatitis C treatment has since been revolutionized by DAAs. Some clinical comparisons were not placebo-controlled.
Questions This Raises
- ?Could thymosin alpha-1 enhance checkpoint immunotherapy for cancer?
- ?Should thymosin alpha-1 be used for immune reconstitution after COVID-19?
- ?What is the global regulatory trajectory for new indications?
Trust & Context
- Key Stat:
- Multi-indication versatility Phase III HCV, Phase II HBV, cancer survival benefit, and HIV immune restoration — all with minimal side effects from a single peptide drug
- Evidence Grade:
- Moderate to strong evidence from a comprehensive pharmaceutical review incorporating all available clinical trial data across multiple indications.
- Study Age:
- Published in 2002. Thymosin alpha-1 (Zadaxin) is now approved in 30+ countries, primarily for hepatitis B and as an immune adjuvant.
- Original Title:
- Thymosin alpha1. SciClone Pharmaceuticals.
- Published In:
- Current opinion in investigational drugs (London, England : 2000), 3(5), 698-707 (2002)
- Authors:
- Billich, Andreas
- Database ID:
- RPEP-00715
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
What diseases can thymosin alpha-1 treat?
It's most established for hepatitis B (approved in 30+ countries), with clinical data also supporting hepatitis C (with interferon), cancer (as a chemotherapy adjuvant), and HIV immune recovery.
Is it safe?
Thymosin alpha-1 has an excellent safety record across thousands of patients in clinical trials. Side effects are typically mild — occasional injection site reactions and rarely flu-like symptoms. It doesn't suppress immunity like many other immune drugs.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-00715APA
Billich, Andreas. (2002). Thymosin alpha1. SciClone Pharmaceuticals.. Current opinion in investigational drugs (London, England : 2000), 3(5), 698-707.
MLA
Billich, Andreas. "Thymosin alpha1. SciClone Pharmaceuticals.." Current opinion in investigational drugs (London, 2002.
RethinkPeptides
RethinkPeptides Research Database. "Thymosin alpha1. SciClone Pharmaceuticals." RPEP-00715. Retrieved from https://rethinkpeptides.com/research/billich-2002-thymosin-alpha1-sciclone-pharmaceuticals
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.